Back to All Events

Oncologic Drugs Advisory Committee (OADC)

  • IQVIA Solutions Denmark A/S Denmark (map)

On Friday, April 28, 2023, the Oncologic Drugs Advisory Committee (ODAC) will discuss a supplemental new drug application (sNDA 208558/S–025), for LYNPARZA (Olaparib) tablets, submitted by AstraZeneca Pharmaceuticals LP. The proposed indication (use) for this product is in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with Metastatic castration-resistant prostate cancer (mCRPC).

Source:: https://www.fda.gov/advisory-committees/advisory-committee-calendar/april-28-2023-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04282023
Earlier Event: April 26
Blood Products Advisory Committee
Later Event: May 9
Nonprescription Drugs Advisory Committee (NDAC) and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee (ORUDAC)